NexImmune Inc Ordinary Shares NEXI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NEXI is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.65
- Day Range
- $3.45–3.59
- 52-Week Range
- $1.25–16.60
- Bid/Ask
- $3.50 / $3.58
- Market Cap
- $4.91 Mil
- Volume/Avg
- 5,318 / 104,689
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 50
- Website
- https://www.neximmune.com
Valuation
|
Metric
|
NEXI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NEXI
|
|---|---|
Quick Ratio | 0.91 |
Current Ratio | 1.06 |
Interest Coverage | — |
Quick Ratio
NEXI
Profitability
|
Metric
|
NEXI
|
|---|---|
Return on Assets (Normalized) | −116.74% |
Return on Equity (Normalized) | −165.99% |
Return on Invested Capital (Normalized) | −163.66% |
Return on Assets
NEXI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xymydsqrxs | Jxlcc | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jlbbqpvm | Fsjwg | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gnlrjlg | Wxwtxv | $98.8 Bil | |
MRNA
| Moderna Inc | Jjtsjrnbr | Pzqm | $38.8 Bil | |
ARGX
| argenx SE ADR | Cdswfpqzq | Sjxf | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Jpkbvwyh | Hgpt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Shgtntxj | Qfscjn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qwgqzvhwv | Lmlpkk | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dsdwtqgnr | Jzdvcdh | $12.4 Bil | |
INCY
| Incyte Corp | Gypnxyn | Bcfzbzd | $11.9 Bil |